Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors

被引:19
|
作者
Kanamori, Masayuki [1 ]
Kumabe, Toshihiro [1 ]
Sonoda, Yukihiko [1 ]
Nishino, Yoshikazu [2 ]
Watanabe, Mika [3 ]
Tominaga, Teiji [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Miyagi Canc Ctr, Res Inst, Div Epidemiol, Natori, Miyagi 9811293, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan
关键词
Oligodendroglioma; Dissemination; Predictive factors; Nestin Ki-67; LOW-GRADE OLIGODENDROGLIOMAS; PHASE-III TRIAL; GLIOBLASTOMA-MULTIFORME; PROGNOSTIC-SIGNIFICANCE; EXPRESSION; GLIOMAS; CHEMOTHERAPY; RADIOTHERAPY; MARKERS; NESTIN;
D O I
10.1007/s11060-008-9762-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pattern of recurrence and predictive factors for tumor progression, dissemination and survival in oligodendroglial tumors were investigated. 56 consecutive patients with oligodendroglial tumors were retrospectively analyzed to determine the predictive significance of various factors, including World Health Organization grade, loss of chromosomes 1p and 19q, and immunohistochemical features of TP53, O-6-methylguanine-deoxyribonucleic-acid-methyltransferase, CD44H, nestin, and Ki-67. Eleven patients developed dissemination, and had significantly shorter post-progression survival compared to ten patients with local recurrence. Univariate analysis showed that retention of chromosome 1p or 19q, Ki-67 labeling index a parts per thousand yen 25%, diffuse expression of nestin, and p53 labeling index a parts per thousand yen 10% were unfavorable factors for overall, progression-free, and dissemination-free survival. Multivariate analysis showed that Ki-67 labeling index a parts per thousand yen 25% and diffuse expression of nestin were significant for dissemination-free survival. In conclusion, post-progression survival shows significant differences between patients with local and disseminated recurrence. Ki-67 labeling index and nestin expression pattern are useful markers to predict dissemination.
引用
收藏
页码:219 / 228
页数:10
相关论文
共 50 条
  • [21] Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma
    Fan, Songhua
    Meng, Delong
    Xu, Tao
    Chen, Yuanyuan
    Wang, Jingkun
    Li, Xiaoying
    Chen, Hongyan
    Lu, Daru
    Chen, Juxiang
    Lan, Qing
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [22] Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting
    Kassik, Marie-Theres
    Vordermark, Dirk
    Kornhuber, Christine
    Medenwald, Daniel
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [23] Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
    Caulet, Morgane
    Lecomte, Thierry
    Bouche, Olivier
    Rollin, Jerome
    Gouilleux-Gruart, Valerie
    Azzopardi, Nicolas
    Leger, Julie
    Borg, Christophe
    Douillard, Jean-Yves
    Manfredi, Sylvain
    Smith, Denis
    Capitain, Olivier
    Ferru, Aurelie
    Moussata, Driffa
    Terrebone, Eric
    Paintaud, Gilles
    Ternant, David
    CLINICAL PHARMACOKINETICS, 2016, 55 (11) : 1381 - 1394
  • [24] Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer
    Chirila, Costel
    Odom, Dawn
    Devercelli, Giovanna
    Khan, Shahnaz
    Sherif, Bintu N.
    Kaye, James A.
    Molnar, Istvan
    Sherrill, Beth
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (05) : 623 - 634
  • [25] The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma
    Gerestein, C. G.
    Eijkemans, M. J. C.
    de Jong, D.
    van der Burg, M. E. L.
    Dykgraaf, R. H. M.
    Kooi, G. S.
    Baalbergen, A.
    Burger, C. W.
    Ansink, A. C.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2009, 116 (03) : 372 - 380
  • [26] Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
    Hamada, Tsuyoshi
    Nakai, Yousuke
    Isayama, Hiroyuki
    Yasunaga, Hideo
    Matsui, Hiroki
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Matsubara, Saburo
    Yamamoto, Natsuyo
    Tada, Minoru
    Koike, Kazuhiko
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 11 - 20
  • [27] IDH1 mutation is associated with improved resection rates, progression-free survival and overall survival in patients with anaplastic astrocytomas
    Ahmeti, Hajrullah
    Kiese, Daniel
    Freitag-Wolf, Sandra
    Kalab, Michael
    Roecken, Christoph
    Jansen, Olav
    Mehdorn, Maximilian H.
    Synowitz, Michael
    JOURNAL OF NEURO-ONCOLOGY, 2024, 169 (02) : 423 - 435
  • [28] Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
    Li, Jiayi
    Cao, Dongyan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL
    Da Broi, Michele
    Jahr, Guro
    Beiske, Klaus
    Holte, Harald
    Meling, Torstein R.
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 73 : 25 - 32
  • [30] Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
    Matulonis, Ursula A.
    Oza, Amit M.
    Ho, Tony W.
    Ledermann, Jonathan A.
    CANCER, 2015, 121 (11) : 1737 - 1746